Status:
COMPLETED
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Wound of Skin
Wound Heal
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 114 patients who have their skin can...
Detailed Description
Healing of a cutaneous defect by second intention is a complex process. Migration of fibroblasts, keratinocytes, and other cell types to the site of defect and their proliferation under stimulation by...
Eligibility Criteria
Inclusion
- Age greater than 18 years
- Open surgical wound ≤1.5cm
- No hypersensitivity with use of 0.25% timolol gel
Exclusion
- Age less than 18 years of age
- Open surgical wound \>1.5cm
- Pregnant women
- Use of systemic retinoids within 1 month
- Any hypersensitivity with use of 0.25% timolol gel
Key Trial Info
Start Date :
August 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT03452072
Start Date
August 20 2018
End Date
June 30 2021
Last Update
January 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohs and Dermatologic Surgery Center, Brigham and Women's Hospital
Boston, Massachusetts, United States, 02130